Rare diseases
Investigational molecules
Locations
Halderstrasse 29, Innenstadt, 86150 Augsburg, Germany
Haematologie-Onkologie im Zentrum MVZ GmbH in Augsburg, Germany specialises in clinical trials of conditions such as Breast cancer, Hormone receptor positive HER2 negative breast cancer, Breast cancer female, Triple negative breast cancer, and other specialisations. This site conducts important research.
The medical center is at the forefront of breast cancer research, focusing on innovative therapies for various subtypes, including HER2-positive and hormone receptor-positive breast cancers.
Through clinical trials like ADAPT-HER2-IV and CAPItello-292, the center is pioneering personalized treatment approaches, enhancing pathologic complete response rates and improving progression-free survival.
Specializing in advanced gastrointestinal cancers, the center explores cutting-edge treatment combinations to improve patient outcomes.
The GOBLET study exemplifies the center's commitment to integrating biomarker research with clinical applications, enhancing the efficacy and safety of novel therapeutic combinations.
The center is a leader in the study of hematological malignancies, focusing on high-risk conditions such as chronic lymphocytic leukemia and polycythemia vera.
Through trials like the GAVE study and HU-F-AIM, the center is advancing the understanding of genetic risk factors and resistance mechanisms, paving the way for more effective treatments.
Clinical trials currently enrolling participants at this site.
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
GermanyStudy on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
GermanyStudy on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
GermanyEIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors
GermanyStudy of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer
GermanyA study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer
GermanyStudy of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk
GermanyStudy of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy
GermanyStudy of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
GermanyStudy on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors
GermanyStudy on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients
GermanyStudy on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
GermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
